Pereyra-Rodriguez, Jose JuanPoveda, José LuisRivero, AlvaroSerra-Baldrich, EstherSilvestre, Juan FranciscoArmario-Hita, José CarlosCalleja, Miguel AngelCarrascosa, Jose ManuelFlorez, AngelesHerranz, PedroComellas, MartaOrtiz de Frutos, Francisco Javier2025-06-102025-06-102024-01-01Pereyra‐Rodríguez JJ, Poveda JL, Rivero A, Serra‐Baldrich E, Silvestre JF, Armario‐Hita JC et al. Assessing the value of moderate‐to‐severe atopic dermatitis treatment using multi‐criteria decision analysis (MCDA). JEADV 2024;38:e59‐e620926-9959https://hdl.handle.net/10668/28520The increased understanding of atopic dermatitis (AD) pathophysiology has shed light on the underlying immunologic mechanisms and spurred the development of novel, more precisely targeted therapies. As new agents become available, assessing their added value is advisable. Yet the value of novel health interventions sometimes remains largely unmeasured and inadequately understood. Value assessment is challenging since it involves assessing the extent to which it meets current unmet needs. Therefore, it is necessary to establish the most relevant health outcomes from different stakeholders' perspectives.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Atopic dermatitisMulti‑criteria decision analysis (MCDA)Health-related quality of life (HRQoL)Pruritus reductionDisease activity controlDecision MakingDecision Support TechniquesDermatitis, Atopicletter37594914open accessDermatitis atópicaAnálisis de decisión multicriterioCalidad de vida relacionada con la saludReducción del pruritoControl de la actividad de la enfermedad10.1111/jdv.19432